Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Completed1
Other1

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT04056247Active Not Recruiting
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more
PrincipalinvestigatorStart date: 2019-10-01

Research Network

Collaboration Network

42 collaborators·89 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Michal Lotem, MD

Hadassah Medical Organization

Similar
3 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungStage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant Melanoma+3 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score64%

Ido Wolf, MD

Tel-Aviv Sourasky Medical Center

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Antony Magliocco, MD

Protean BioDiagnostics

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Eugenie Younger, MD

Gloucestershire Hospitals NHS Foundation Trust

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Andreas Polychronis, MD

Mount Vernon Cancer Centre

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Adam Berger, MD

Rutgers Cancer Institute

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Astrid Ammendola, MD

Asklepios Klinik Gauting GmbH

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Igor Puzanov, MD

Roswell Park

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Louise Medley, MD

Torbay and South Devon NHS foundation

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Andrew Conn, MD

Bradford Teaching Hospitals

Similar
1 trials

Shared therapeutic areas:

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more

Worked with same sponsors:

OncoHost Ltd.
Collaborated on 1 trial
Similarity Score54%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT04056247PrincipalInvestigator

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Stage III Unresectable Non-Small Cell Lung CancerStage IIIb-d Malignant MelanomaStage IV Malignant Melanoma+2 more
Active Not Recruiting
NCT00840125Phase 2PrincipalInvestigator

Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment

Non-Small Cell Lung Cancer
Completed

All 2 trials loaded